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Immunosuppressed patients are at risk for developing Epstein-Barr Virus (EBV)-positive lymphomas that express the major
EBV oncoprotein, LMP1. Although increasing evidence suggests that a small number of lytically infected cells may promote
EBV-positive lymphomas, the impact of enhanced lytic gene expression on the ability of EBV to induce lymphomas is unclear.
Here we have used immune-deficient mice, engrafted with human fetal hematopoietic stem cells and thymus and liver tissue, to
compare lymphoma formation following infection with wild-type (WT) EBV versus infection with a “superlytic” (SL) mutant
with enhanced BZLF1 (Z) expression. The same proportions (2/6) of the WT and SL virus-infected animals developed B-cell lym-
phomas by day 60 postinfection; the remainder of the animals had persistent tumor-free viral latency. In contrast, all WT and SL
virus-infected animals treated with the OKT3 anti-CD3 antibody (which inhibits T-cell function) developed lymphomas by day
29. Lymphomas in OKT3-treated animals (in contrast to lymphomas in the untreated animals) contained many LMP1-express-
ing cells. The SL virus-infected lymphomas in both OKT3-treated and untreated animals contained many more Z-expressing
cells (up to 30%) than the WT virus-infected lymphomas, but did not express late viral proteins and thus had an abortive lytic
form of EBV infection. LMP1 and BMRF1 (an early lytic viral protein) were never coexpressed in the same cell, suggesting that
LMP1 expression is incompatible with lytic viral reactivation. These results show that the SL mutant induces an “abortive” lytic
infection in humanized mice that is compatible with continued cell growth and at least partially resistant to T-cell killing.
Epstein-Barr virus (EBV) is a human herpesvirus that is asso-ciated with a variety of different types of human B-cell lym-
phomas, including endemic Burkitt lymphoma (BL), Hodgkin
lymphoma (HL), lymphoproliferative disease (LPD) in immu-
nocompromised hosts, and a subset of diffuse large B cell lym-
phomas (DLBCLs) (53). Like all herpesviruses, EBV can infect
cells in either latent or lytic forms. During latent EBV infection,
the virus persists as a nuclear episome and is replicated once
per cell cycle using the host cell DNA polymerase and the viral
EBNA1 protein via the oriP origin of replication (34). EBV can
express up to 9 different viral proteins during latent infection,
and at least three different forms of viral latency (which differ
in regard to the viral protein expression pattern) have been
described (34, 53). EBV-infected cells with type III latency ex-
press all 9 latent viral proteins, and this is the only type of EBV
infection that is sufficient to transform primary B cells in vitro
(34, 53). However, cells with type III latency are highly immu-
nogenic, and tumors with this form of latency are only found in
patients with profound immunosuppression, such as post-
transplant lymphoproliferative disease (PTLD).
Although EBV-infected tumors are composed primarily of
cells with one of the latent forms of EBV infection, increasing
evidence suggests that a small number of tumor cells with the lytic
form of viral protein expression may promote tumor growth (28,
29, 41). We previously showed that B cells harboring a lytically
defective EBV mutant (deleted for the BZLF1 immediate-early
[IE] gene) grow more slowly than cells transformed with wild-
type (WT) virus in a SCID mouse xenograft model (28). More
recently, we found that this lytically defective mutant is also im-
paired for the ability to form lymphomas in a new humanized
mouse model engrafted with human hematopoietic CD34 stem
cells and thymic tissue that represents a largely intact human im-
mune system (41). Since fully lytic EBV infection is thought to
induce host cell killing, the development of drugs that activate
lytic gene expression in tumor cells is being pursued as a potential
treatment for EBV-positive malignancies (20, 21, 46, 51). Consis-
tent with this idea, an EBV mutant (ZV ZV= ZIIR) that has an
abnormally high level of lytic gene expression was recently found
to be highly defective in transforming primary B cells in vitro due
to excessive host cell death following viral infection, as noted in
the accompanying article by Yu et al. (68).
The switch between latent and lytic forms of infection is initi-
ated by expression of the viral immediate-early (IE) protein
BZLF1 (Z). Z is a transcription factor that binds to and activates
the EBV early lytic gene promoters, as well as the promoter of the
other EBV IE protein, BRLF1 (R) (34, 53). Z and R synergistically
induce the expression the early lytic viral genes, which encode the
replication machinery required for viral replication mediated by
the virally encoded DNA polymerase and the oriLyt origin of rep-
lication. Direct Z binding to oriLyt (independent of Z transcrip-
tional function) is required for viral lytic replication. Lytic viral
replication is followed by the expression of the late viral genes,
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which encode the structural viral proteins required for encapsida-
tion and release of infectious viral particles.
In addition to playing an essential role in activating lytic gene
transcription and promoting viral replication, Z exerts numerous
effects on the host cell environment. For example, various in vitro
studies have shown that Z disperses promyelocytic leukemia pro-
tein (PML) bodies in the nucleus (1, 8), binds to and inhibits the
function of the tumor suppressor protein p53 (11, 42, 57), induces
expression of an essential B-cell growth factor, interleukin-6
(IL-6) (29), and inhibits cell cycle progression (11). Z has also
been reported to decrease the expression of several different host
cell proteins involved in immune-mediated killing of EBV-in-
fected cells, including the gamma interferon receptor (49), the
TNFR1 tumor necrosis factor alpha (TNF-) receptor (48), the
CIITA transcription factor (39), and the invariant chain (CD74),
which is an essential chaperone for major histocompatibility com-
plex (MHC) class II antigen presentation (71). In addition, Z in-
teracts directly with the p65 component of NF-B and inhibits its
function (25, 47). However, since many of the previously reported
conclusions were obtained from in vitro studies that used non-
physiological levels of Z and/or were performed outside the con-
text of the intact viral genome, the various effects of Z on the host
cell environment in the context of in vivo viral infection remain
uncertain.
The switch between latent and lytic EBV infection is tightly
regulated by cellular and viral factors at multiple different levels.
The first step in lytic viral reactivation involves activation of the
BZLF1 promoter (Zp) by cellular transcription factors. Lytic EBV
reactivation has been associated with plasma cell differentiation in
humans (36), and the master regulators of plasma cell differenti-
ation, Blimp1 and XBP1, can activate Zp in vitro (5, 10, 62). B-cell
receptor (BCR)-mediated signaling also leads to EBV reactivation
in EBV-infected Burkitt lymphoma lines with type I latency (63).
However, Zp also contains several cis-acting “silencing” motifs
that inhibit its activity and, hence, promote viral latency. Two of
these elements, ZV, and ZV=, are synergistically bound by the
ZEB1 and ZEB2 cellular transcription factors (18, 35, 68, 69), and
knockdown of ZEB1 and ZEB2 in EBV-infected cell lines leads to
enhanced lytic EBV gene expression (18, 19). Another silencing
element, ZIIR (which binds to an as-yet-unidentified cellular pro-
tein), also inhibits Zp activity (40, 67), and a mutant EBV contain-
ing mutations in all three silencing Zp elements (the ZV ZV= ZIIR
triple mutant [tmt]) has more constitutive lytic gene expression in
vitro than mutant viruses in which only the ZV or ZIIR motifs have
been altered (68). Of note, the ZV ZV= ZIIR “superlytic” mutant
(hence referred to here as the “SL” mutant) is highly defective in
establishing viral latency in primary peripheral blood B cells in
vitro due to excessive cell killing. Nevertheless, it can establish
long-term viral latency in 293 cells, although it spontaneously re-
activates much more efficiently than WT virus in these cells, espe-
cially in response to phorbol ester treatment (68). Thus, activation
of Zp requires both the loss of repressors and the presence of
trans-activating factors.
Viral reactivation is also regulated at the level of Z protein
transcriptional and replicative functions. For example, we re-
cently showed that the B-cell-specific cellular Oct-2 protein inter-
acts directly with Z and inhibits its DNA-binding activity, thus
promoting viral latency in B cells (54). The p65 component of
NF-B, as well as the Myc protein, also interacts directly with Z
and inhibits its transcriptional activity (25, 55). Z binding to (and
activation of) many early lytic viral genes requires promoter DNA
methylation (6, 16), and EBV infection of primary B cells does not
result in lytic viral replication until the viral genome has become
methylated (30, 31). Furthermore, phosphorylation of Z residue
173 is required for Z replicative function (and, hence, late gene
expression) but is not important for early gene activation (17),
and direct interaction between Z and p53-BP1 is, likewise, re-
quired for viral replication but not early gene expression (3). In
addition, two different EBV latency proteins (LMP2A and LMP1)
have been reported to inhibit lytic gene reactivation in vitro (2, 43,
44, 52). Thus, accumulating evidence derived from in vitro studies
suggests that Z expression per se in EBV-infected cells will not
always result in early gene expression and/or lytic viral replication.
However, whether “abortive” lytic EBV gene expression (i.e., Z
expression in the absence of viral lytic replication) occurs in vivo,
and under what circumstances, is not clear.
Mice reconstituted with a functional human immune system
may provide a vastly improved model (in comparison to previ-
ously available models) for studying the roles of specific EBV pro-
teins in viral pathogenesis and the development of B-cell lym-
phoma in the context of a largely intact human immune response.
In contrast to previous models (such as the nonobese diabetic/
severe combined immunodeficient [NOD/SCID] mouse), en-
grafted human B cells can undergo class switching, and T cells can
undergo receptor gene rearrangement. Since the human blood
cells are derived from hematopoietic (CD34) stem cells, multiple
different stages in the development of B cells and T cells are pres-
ent. In addition, EBV-infected B cells can engage in interactions
with T cells that might alter the B-cell environment; for example,
EBV-infected B cells may undergo CD40-mediated signaling in
response to contact with CD40 ligand-expressing T cells. EBV-
infected B cells can also migrate to different organs and environ-
ments (including the bone marrow, spleen, lymph nodes, and
engrafted human thymic tissue).
In a recent study, we showed that WT (B95.8 strain) EBV in-
fection in humanized NOD/LtSz-scid/IL2Rnull (NSG) mice re-
constituted with both human fetal CD34 cells and cotransplanted
human thymic tissue [hereafter referred to as “hNSG(thy) mice”]
results in EBV-positive diffuse large B-cell lymphomas (DLBCLs)
in a subset of infected mice, while other mice successfully control
their EBV infection and develop long-term tumor-free viral la-
tency (41). Furthermore, we found that a BZLF1-deleted EBV
mutant produced fewer DLBCLs than the WT virus, although it
was able to establish persistent latent infection in all infected mice
(41). In this study, we investigated the phenotype of the superlytic
(SL) EBV mutant in hNSG(thy) mice to examine the effects of
increased lytic EBV gene expression on viral pathogenesis and
lymphoma formation. Furthermore, we examined the effect of an
anti-CD3 (OKT3) antibody (which inhibits T-cell function) on
the outcome of EBV infection in the hNSG(thy) mouse model.
Our results indicate that the SL mutant is similar to the WT virus
in its ability to induce lymphomas in this model, the SL virus-
infected lymphomas contain BZLF1-expressing cells with an
abortive form of lytic infection, and anti-CD3 OKT3 treatment
dramatically impairs host control of EBV infection in this model.
MATERIALS AND METHODS
EBV viruses. A WT (B95-8 strain) EBV bacmid, p2089, which expresses
the green fluorescent protein (GFP) and a hygromycin B resistance gene,
was constructed using bacterial artificial chromosome technology as de-
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scribed previously (15) and was a gift from Henri-Jacques Delecluse. The
ZV ZV= ZIIR tmt (SL mutant) was derived by site-specific base pair sub-
stitution mutagenesis of the p2089 bacmid as described previously (68).
This mutant contains alterations in three different regions of the BZLF1
promoter (inactivating the ZV and ZV= ZEB-binding motifs as well as the
ZIIR element), and has greatly enhanced BZLF1 expression in compari-
son to the WT EBV in vitro. A WT revertant of p2089-ZV ZV= ZIIR tmt,
p2089-ZV ZV= ZIIRtmt Rev, was likewise constructed by site-specific mu-
tagenesis of the p2089-ZV ZV= ZIIR tmt.
Humanized NOD/LtSz-scid/IL2Rnull mice. Immunodeficient non-
obese diabetic/severe combined immunodeficient (NOD/LtSz-scid/
IL2Rnull) mice were purchased from Jackson Laboratory (catalogue no.
005557) and used at 6 to 10 weeks of age. Human fetal thymus and liver
tissues of gestational ages of 17 to 20 weeks were obtained from Advanced
Bioscience Resource (Miltenyi Biotec, Alameda, CA). The recipient mice
were conditioned with sublethal (2 to 3 Gy) whole-body irradiation and
implanted with fetal thymus and liver fragments under the recipient kid-
ney capsule after irradiation. The mice also received an intravenous (i.v.)
injection of purified CD34 cells isolated from the same fetal liver by the
magnetically activated cell sorter (MACS) separation system (Miltenyi
Biotec, Auburn, CA). The purity of the injected CD34 cells was at least 80
to 90%. At 10 weeks post-immune reconstitution, the levels of human
hematopoietic cells in mice were determined by multicolor flow cytomet-
ric (FCM) analysis using various combinations of the following antibod-
ies: pan-CD45 (clone HI30), CD4 (clone RPA-T4 or OKT4), and CD8
(clone RPA-T8). Antibodies were purchased from commercial sources
directly conjugated to fluorescent dyes. Fluorescence-activated cell sorter
(FACS) analysis was performed on a FACScalibur (Becton, Dickinson,
Mountain View, CA).
Production of infectious virus. Infectious viral particles were pro-
duced from 293 cell lines stably infected with the WT or SL mutant viruses
following transfection with EBV BZLF1 and GP110 expression vectors as
previously described (41). Supernatants were harvested at 72 h posttrans-
fection and filtered through a 0.45-m-pore-size filter. The virus was
concentrated by centrifugation at 18,000 rpm for 3 h using an SW27 rotor,
resuspended in phosphate-buffered saline (PBS) overnight at 4°C, and
then stored at 80°C. To determine the titer of the EBV stock, Raji cells
were infected with serial 10-fold dilutions of virus. After 48 h, cells were
treated with 50 ng/ml phorbol-12-myristate-3-acetate (PMA; Sigma) and
3 mM sodium butyrate (Sigma), and the number of GFP-expressing Raji
cells was counted 24 h later by fluorescence microscopy. Infection of pri-
mary B cells with equal amounts of WT and SL virus (with the titer deter-
mined by the green Raji cell assay) resulted in similar levels of latent viral
transcripts (68), indicating that the accuracy of the green Raji cell titer
assay is not significantly affected by excessive lytic viral gene expression in
SL mutant-infected Raji cells.
EBV infection of mice. Mice were injected intraperitoneally (i.p.) with
30,000 green Raji units (GRU) of WT or SL mutant EBV in 250 l PBS
approximately 10 weeks after engraftment of human cells; successful en-
graftment of human cells was confirmed in each animal prior to EBV
infection. Three different groups of animals were used, with the mice in
each group each being reconstituted from the same donor cells. In the first
group of animals, 3 mice were infected with WT EBV and 3 mice were
infected with the SL mutant. In the second group of animals, 4 mice
were infected with the SL revertant virus (in which the SL alterations were
switched back to the WT virus sequences) and 4 mice were infected with
the SL mutant. Since the WT and SL revertant viruses gave similar phe-
notypes, both here and in prior in vitro studies (68), results from group 1
and group 2 animals were combined, and the WT and SL revertant viruses
are both referred to here as “WT virus” in results. In the group 2 experi-
ment, one mouse infected with each virus was sacrificed at days 3 and 12
postinfection (p.i.) to examine the viral protein expression at early time
points; these mice were not considered when calculating the lymphoma
incidence. In the third group of animals, 3 mice were infected with WT
virus and 3 mice were infected with the SL mutant virus. In this experi-
ment, mice were treated with an anti-CD3 antibody (OKT3) starting 1 day
after EBV infection and continuing daily (except Sunday) thereafter until
the time of euthanasia. Mice were sacrificed at day 60 postinfection, unless
they became clinically ill earlier. Following euthanasia, multiple different
organs (including the lungs, transplanted thymus, spleen, pancreas, liver,
and abdominal lymph nodes) were formalin fixed and then examined
using a variety of different techniques to determine if animals had persis-
tent EBV infection and/or EBV-positive lymphomas and to assess the viral
protein expression pattern. Analysis performed for all animals included
hematoxylin and eosin (H&E) staining, EBV-encoded RNA (EBER) in
situ hybridization, and immunohistochemical (IHC) staining using anti-
bodies directed against CD20 (B-cell marker), CD3 (T-cell marker),
CD74, MHC class I, and the EBV proteins EBNA1, EBNA2, LMP1,
LMP2A and BZLF1, gp125, and gp350.
Anti-CD3 antibody treatment. OKT3 antibody was purchased from
Imgenex (San Diego, CA). Mice received 2 g of antibody intravenously
(i.v.) per day, starting 1 day after EBV infection and continuing for 6 days
a week until the time of euthanasia.
Detection of EBERs by in situ hybridization. EBER in situ hybridiza-
tion studies were performed using the PNA in situ hybridization (ISH)
detection kit (DakoCytomation) according to the manufacturer’s proto-
col as previously described (41).
IHC. Formalin-fixed, paraffin-embedded tissue sections were depar-
affinized and then examined by immunohistochemistry (IHC) as previ-
ously described (41). The antibodies used are listed in Table 1.
Real-time qPCR to measure EBV viral load in plasma. Quantitative
PCR (qPCR) targeting the BamHIW region of the EBV genome was used
to measure EBV viral load in plasma samples using TaqMan technology as
previously described (56). Prior to DNA extraction, plasma was spiked
with exogenous internal positive control DNA (Applied Biosystems, Fos-
ter City, CA) to control for the effectiveness of extraction and amplifica-
tion. A standard curve was generated using serial 10-fold dilutions of
Namalwa DNA. To determine whether the viral DNA in plasma was from
lysed infected cells or from viral particles, in samples that had very high
EBV loads, the assay was repeated with or without pretreatment of the
sample with DNase I (Roche Diagnostics, GmbH, Mannheim, Germany)
at 37°C for 30 min according to the manufacturer’s instructions.
Viral genome methylation analysis. Total genomic DNA was isolated
from livers of infected animals using the DNeasy tissue kit (Qiagen).
Bisulfite modification of genomic DNA was performed using the EpiTect
bisulfite kit (Qiagen) in accordance with the manufacturer’s instructions.
The modified DNA was amplified by PCR using the following EBV
BMRF1 promoter primers: 5=-GATTAAGGGTTATTTGGATTTAGGAG
T-3= and 5=-TCAAAAATCATCTACCACCAACATA-3=. The thermal cy-
cler conditions for the PCR were as follows: 1 cycle at 95°C for 15 min,
followed by 14 cycles of 95°C for 30 s and 57°C to 50°C for 30 s with a
TABLE 1 Antibodies used for immunohistochemistry in this study
Antibody Clone Source or manufacturer Dilution
CD20 H1 BD Pharmingen 1:600
CD3 Polyclonal DakoCytomation 1:200
CD8 SP16 Biocare Medical, LLC. 1:50
LMP1 CS.1-4 DakoCytomation 1:600
LMP2A 15F9 Santa Cruz Biotechnology, Inc. 1:100
EBNA1 EB14 Gift from Richard R. Burgess 1:1,000
EBNA2 PE2 Leica Microsystems 1:100
BZLF1 BZ1 Santa Cruz Biotechnology, Inc. 1:200
BMRF1 G3-E31 Vector Laboratories 1:200
BALF2 OT13D Gift from Jaap M. Middeldorp 1:1,000
gp350 72A1 Gift from Eric C. Johannsen 1:100
VCA-gp125 L2 Chemicon International 1:100
CD74 LN2 BD Biosciences 1:100
MHC class I Polyclonal Santa Cruz Biotechnology, Inc. 1:50
Ma et al.
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gradual decrease of melting temperature (Tm) of 0.5°C, followed by 72°C
for 1 min, and then 36 cycles of 95°C for 30 s, 50°C for 30 s, 72°C for 1 min,
and a final extension of 72°C for 7 min. PCR products were agarose gel
purified with a Qiagen gel extraction kit and then cloned into the pGEM-T
Easy vector system (Promega) following the manufacturer’s instructions.
Ten clones were sequenced using both T7 and SP6 primers.
RESULTS
The SL EBV mutant can induce lymphomas in hNSG(thy) mice
in the presence and absence of a T-cell-depleting (OKT3) anti-
body. In our previous study (41), we found that while some WT
EBV-infected hNSG(thy) animals successfully control their infec-
tion and develop long-term tumor-free viral latency, others de-
velop EBV-positive diffuse large B-cell lymphoma (41). To deter-
mine if enhanced lytic viral gene expression affects the outcome of
EBV infection in the hNSG(thy) mouse model, mice were infected
(following successful engraftment of human cells) with equal
amounts of the WT or SL viruses (30,000 green Raji cell units i.p.).
As shown in Fig. 1A, similar numbers of lymphomas were found
in the WT- and SL virus-infected mice at the time of euthanasia
(day 60 postinfection). Two of six of the WT virus-infected
animals and 2/6 of the SL virus-infected animals developed
lymphomas.
To examine the WT virus and SL mutant virus phenotypes
when T-cell function is compromised, hNSG(thy) mice were in-
fected with the WT or SL viruses and then treated daily with the
anti-CD3 monoclonal antibody OKT3 (2 g/animal/day i.v.)
starting 1 day after infection and continuing until the time of
euthanasia. Treatment with this antibody greatly decreased the
number of T cells in peripheral blood of mice, as shown in Fig. 2.
As shown in Fig. 1B, OKT3 antibody remarkably inhibited the
ability of hNSG(thy) mice to control either WT or SL virus infec-
tion. Three of three WT virus-infected animals as well as 3/3 SL
virus-infected animals all developed large B-cell lymphomas by
day 29 postinfection when treated with the antibody.
The SL mutant and WT virus-infected animals have similar
viral loads in the blood, but OKT3 treatment increases viral load
following either SL or WT virus infection. To examine more
quantitatively the number of virally infected cells in the WT versus
SL virus-infected animals, blood was collected at various time
points after infection and a quantitative PCR assay was performed
to determine the amount of EBV DNA present in the plasma. As
shown in Fig. 3A, in the absence of OKT3 antibody treatment,
EBV infection was generally very well controlled in this human-
ized mouse model, and most of the WT virus-infected animals, as
well as the SL virus-infected animals, had either undetectable or
very low plasma viral loads (less than 50 copies of EBV per ml).
The two animals with the highest viral loads (one WT virus-in-
fected animal and one SL virus-infected animal) each had lym-
phomas at the time the plasma was collected, and thus the higher
circulating EBV DNA levels in these animals were likely due to
lysed tumor cell DNA. However, even the animals that were found
to have lymphomas had relatively low viral loads in the plasma (no
greater than 200 copies per ml), consistent with the relatively small
size of most EBV-induced lymphomas in the hNSG(thy) model in
the absence of OKT3 treatment.
In contrast, OKT3-treated animals often had much higher cir-
culating viral loads (up to 60,000 copies of viral DNA per ml of
plasma) (Fig. 3B), consistent with the finding that OKT3-treated
animals developed large lymphomas at early time points. Some-
what surprisingly, the WT and SL viruses resulted in similar viral
loads in infected animals. To determine whether the viral DNA in
plasma was from lysed EBV-infected lymphoma cells or from viral
particles, the assay was repeated in the four animals with the high-
est viral loads (two WT virus-infected animals and two SL virus-
infected animals), with or without pretreatment of the samples
with DNase I. In each case, DNase I treatment eliminated at least
98.5% of the measured viral DNA load (data not shown), indicat-
ing that the viral DNA load was derived from lysed tumor cells.
SL virus induces DLBCLs that contain many Z-expressing
cells. Similar to the lymphomas induced by WT EBV, the SL virus-
infected lymphomas had histological features of diffuse large B-
cell lymphomas heavily infiltrated with T cells in the absence of
anti-CD3 treatment (Fig. 4A). As expected, tumors had fewer in-
filtrating T cells in the OKT3-treated animals (Fig. 4B). To deter-
mine if the SL virus-induced lymphomas have more cells ex-
pressing Z than the WT virus-induced lymphomas, EBNA2 and
Z IHC staining was performed on adjacent tumor slides. As
predicted by its in vitro phenotype, the SL virus-infected lym-
phomas contained many more Z-expressing cells (up to 30% of
cells in some lymphomas) than did the WT virus-infected lym-
phomas (Fig. 4C and D). Nevertheless, since EBNA2-express-
ing cells were still much more common than Z-expressing cells
in SL virus-infected lymphomas, clearly not all SL virus-in-
fected lymphoma cells express Z.
Z lymphoma cells can divide. Z has been reported to inhibit
FIG 1 SL EBV mutant can induce lymphoma in hNSG(thy) mice. The per-
centage of mice developing EBV-positive tumors in SL versus WT virus-in-
fected animals is shown. (A) Animals without OKT3 treatment; (B) animals
treated with OKT3.
FIG 2 OKT3 treatment depleted peripheral blood human T cells in all treated
mice. Peripheral blood was collected from hNSG(thy) mice at days 0 and 12
post-OKT3 treatment. Human CD45, CD19, CD3, CD4, and CD8 cell popu-
lations were detected by flow cytometry. Dead cells were excluded from the
analysis. Results are presented as the percentage of positively staining cells with
each antibody in comparison to the total leukocyte population.
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cell cycle progression in vitro (11), and lytic EBV infection can kill
at least some EBV-infected cell lines (22, 32). Thus, the finding
that up to 30% of the SL virus-infected lymphoma cells express Z,
yet the SL virus still efficiently induces lymphoma, was unex-
pected. The appearance of the Z-positive lymphoma cells versus
nearby Z-negative lymphoma cells was not found to be correlated
with any particular cytologic alteration (data not shown). How-
ever, in contrast to the reported inhibitory effect of Z on cell cycle
progression in vitro, we observed that 2.3% of Z-expressing lym-
phoma cells were actively dividing (Fig. 5A), even in the presence
of many surrounding CD8 T cells (Fig. 5B), in comparison to
1.2% of the total EBNA2-expressing lymphoma cells. Thus, Z-ex-
pressing cells retain the ability to proliferate in this in vivo lym-
phoma model.
The SL mutant establishes an abortive form of lytic EBV in-
fection in lymphoma cells. The findings that WT and SL virus-
infected animals have similar viral loads and that Z lymphoma
cells can divide suggested that SL virus-infected lymphoma cells
might not support fully lytic viral infection. To examine this pos-
sibility further, lymphoma specimens were stained with antibod-
ies directed against the immediate-early Z protein, the early lytic
viral proteins BMRF1 and BALF2, and the late lytic viral proteins
gp125 and gp350/220. Each of these antibodies was validated for
IHC use in paraffin-fixed tissue using Akata BL cells treated in
vitro with or without the lytic inducing agent anti-IgG. As shown
in Fig. 6, in the absence of OKT3 antibody treatment, Z-positive
lymphoma cells did not detectably express any of the four lytic
viral proteins examined, although each of these early and late lytic
EBV proteins was easily detected in anti-IgG treated Akata cells.
The lymphomas of OKT3-treated animals expressed the early lytic
viral proteins (BMRF1 and BALF2), but still did not detectably
express late lytic viral proteins (Fig. 6). The findings that late lytic
viral proteins are not detected in either the presence or absence of
OKT3 treatment and that the viral loads of the SL and WT virus-
infected animals are similar suggest that the majority of Z-express-
ing lymphoma cells in the humanized mouse model are not per-
missive for the lytic form of viral DNA replication even when
T-cell function is compromised.
Since methylation of the EBV genome has been shown to be
required for Z activation of many early lytic promoters, as well as
the lytic form of viral DNA replication (30), we examined the
methylation state of the BMRF1 promoter in an SL virus-infected
lymphoma (in an animal not treated with OKT3) that expressed Z
but not BMRF1, using bisulfite sequencing analysis. As shown in
Fig. 7, the BMRF1 early viral promoter was found to be highly
methylated in this lymphoma, making it unlikely that the lack
of fully lytic infection was due to inadequate methylation of the
viral genome. In addition, since the lytically replicated form of
the viral genome is unmethylated, this result confirms that the
Z-expressing lymphoma cells contain very little, if any, lytically
replicated EBV.
Z lymphoma cells have decreased expression of CD74 and
MHC class I. The finding that SL virus-infected lymphomas con-
tain so many Z cells was also surprising (particularly in the ani-
mals not treated with OKT3) because cytotoxic T cells directed
against the Z protein are highly abundant in mononucleosis pa-
tients and are thought to contribute to clearance of virally infected
cells (58, 60). Since Z was recently reported to decrease expression
of the essential MHC class II peptide chaperone protein, CD74, in
vitro (71), we performed Z-CD74 costaining studies on SL virus-
infected lymphoma cells to determine if Z likewise inhibits CD74
expression in the hNSG(thy) model. These studies confirmed that
most Z-expressing cells do not express CD74 (Fig. 8). In addition,
since early lytic EBV infection has been reported to decrease MHC
class I expression (13), we performed Z-MHC class I costaining
studies. Z cells had decreased expression of MHC class I relative
to the surrounding cells (Fig. 8). These results suggest that Z ex-
pression may be tolerated (even selected for) in lymphomas in the
FIG 3 The SL mutant and WT EBV-infected animals have similar viral loads in plasma, but OKT3 treatment increases viral load after EBV infection. qPCR was
performed (using primers to detect the BamHIW repeat region of the EBV genome) on purified plasma DNA collected from SL mutant and WT EBV-infected
animals at various days postinfection as indicated. (A) Viral load from animals without OKT3 treatment. The boxed dots indicate the two animals that developed
tumors. (B) Viral load from animals treated with OKT3. The boxed dots indicate animals that were sacrificed at day 25 due to significant weight loss. All six
animals had tumors.
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hNSG(thy) model at least partly because Z expression reduces the
ability of T cells to recognize infected lymphoma cells.
Lymphomas in OKT3-treated animals have many more
LMP1/LMP2A-expressing cells. We previously showed that
EBV-induced lymphomas in the hNSG(thy) mouse model usually
have surprisingly few cells expressing the LMP1 viral oncoprotein
relative to the number of cells expressing EBNA2 (41). A recent
LMP1 transgenic mouse model study found that LMP1 induces
B-cell lymphomas in the presence, but not absence, of anti-T-cell-
depleting antibodies and reported that functional T cells eliminate
LMP1-expressing B cells in transgenic mice (70). To determine if
OKT3 treatment affects the number of LMP1-positive lymphoma
cells in EBV-infected hNSG(thy) mice, EBNA2-LMP1 costaining
studies were performed on lymphoma specimens. Similar to our
previous findings, very few EBNA2-positive lymphoma cells (less
than 1%) coexpressed LMP1 in mice that were not treated with
OKT3 (Fig. 9A). In contrast, EBV-infected mice treated with
OKT3 developed lymphomas that contained numerous cells co-
expressing EBNA2 and LMP1 (Fig. 9B). LMP2A expression was
also greatly increased in animals treated with anti-CD3 antibody
(data not shown). The EBNA2/LMP1 costaining studies also re-
vealed the presence of a small population of lymphoma cells with
the type IIA latency form characteristic of Hodgkin lymphomas
(LMP1 EBNA2) (Fig. 9C). Together, these results indicate that
OKT3 treatment is associated with greatly increased expression of
LMP1 and LMP2A in EBV-infected B cells in hNSG(thy) human-
ized mice, consistent with the rapid onset of EBV-induced lym-
phomas in these animals.
Lytic viral protein and LMP1/LMP2A expression are mutu-
ally exclusive. Since both LMP1 and LMP2A have been proposed
to inhibit lytic viral reactivation in various EBV-infected cell line
models in vitro (2, 43, 44, 52), we performed LMP1-BZLF1 and
LMP1-BMRF1 costaining studies with SL virus-infected lym-
phoma cells to determine if LMP1 expression is inversely corre-
lated with lytic viral protein expression. Consistent with the re-
sults of previous in vitro studies, BMRF1 expression was never
observed in cells expressing LMP1 and Z expression occurred at
only a very low level in cells expressing LMP1 (Fig. 10). Z expres-
FIG 4 SL virus induces DLBCLs with upregulated BZLF1 expression. (A) SL mutant EBV-induced DLBCL from a non-OKT3-treated animal was stained for
H&E, EBV EBNA1 protein, CD20, and CD3 (100 magnification). Large atypical tumor cells showing CD20 membrane staining were infiltrated by numerous
small CD3-staining T cells. (B) SL EBV-induced DLBCL from an OKT3-treated animal was stained for H&E, EBV EBNA1 protein, CD20, and CD3 (100
magnification). (C) EBNA2 and BZLF1 staining of DLBCLs in SL mutant EBV-infected (upper panel) and WT EBV-infected (lower panel) (100 magnification)
animals not treated with OKT3. (D) EBNA2 and BZLF1 staining of DLBCLs in SL EBV-infected (upper panel) and WT EBV-infected (lower panel) (100
magnification) animals treated with OKT3.
FIG 5 BZLF1-expressing lymphoma cells can divide in hNSG(thy) mice. (A)
BZLF1 staining of a DLBCL from an SL mutant EBV-infected animal (without
OKT3 treatment). (B) Dual-color immunohistochemistry was performed us-
ing anti-BZLF1 (black) and anti-CD8 (pink) antibodies in an SL-EBV-infected
animal (without OKT3 treatment). Dividing cells are indicated by black ar-
rows (100 magnification).
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sion and LMP2A expression were likewise found to be mutually
exclusive (Fig. 10). These results suggest that LMP1 and/or
LMP2A inhibits BZLF1 expression in lymphoma cells and that the
lytically infected population of lymphoma cells in this model is
distinct from the subset of cells containing the classic type III form
of viral latency (LMP1 EBNA2). Our results do not exclude the
possibility that BZLF1inhibits LMP1 and LMP2A expression.
The SL mutant establishes asymptomatic viral latency in
some hNSG(thy) mice. Since the majority (4/6) of the SL virus-
infected animals did not develop lymphoma in the absence of
OKT3 treatment, we asked if the SL mutant is impaired for the
ability to establish long-term viral latency in the tumor-free ani-
mals. Tissues harvested from a variety of different organs of each
EBV-infected animal (including spleen, liver, lymph nodes, lungs,
kidney, and implanted thymic tissue) were examined for the pres-
ence of latently infected cells using EBER in situ hybridization and
anti-EBNA1 immunostains. Other than two animals sacrificed at
day 3 postinfection, each of the WT and SL virus-infected animals
had definite EBER-positive and EBNA1-positive cells (most com-
monly in the spleen) at the time of euthanasia (Fig. 11). Of note,
the number of EBV-infected cells present in the tumor-free WT
and SL virus-infected animals was usually extremely low (i.e., only
a few positive cells found per spleen section), consistent with the
ability of these animals to successfully control their EBV infection.
No Z-expressing cells or LMP1-expressing cells were detected in
any of the tumor-free, SL or WT virus-infected animals eutha-
nized at day 60 postinfection (Fig. 11) (data not shown). These
results indicate that the SL virus can establish viral latency in some
hNSG(thy)-infected mice and that long-term asymptomatic in-
fection is associated with suppression of Z and LMP1 expression.
To determine if there is an early burst of lytic gene expression
prior to the onset of viral latency, we also sacrificed WT and SL
virus-infected mice at two earlier time points postinfection to ex-
amine the amounts of EBER, Z, and BMRF1 expression. Z cells
were detected in SL virus-infected animals at days 12 and day 37
postinfection (Fig. 11). Animals examined at day 3 postinfection
FIG 6 The SL EBV mutant induces an abortive form of lytic EBV infection in lymphoma cells. Anti-BZLF1, anti-BMRF1, anti-BALF2, anti-gp125, and
anti-350/220 staining was performed as indicated (100 magnification) to examine expression of immediate-early (BZLF1), early lytic (BMRF1 and BALF2), and
late lytic (gp125 and gp350/220) viral proteins in SL EBV-infected animals. Formalin-fixed and paraffin-embedded Akata (AK) BL cells treated in vitro without
or with anti-IgG pretreatment as indicated in the upper two panels served as the baseline and induced controls for lytic EBV protein expression, respectively.
Abortive lytic infection is seen in animals with or without OKT3 treatment, as indicated in the lower two panels.
FIG 7 The EBV BMRF1 early lytic promoter is highly methylated in EBV-
induced DLBCLs. DNA isolated from an SL mutant EBV-infected DLBCL
without OKT3 treatment was bisulfite treated and sequenced. The black dots
indicate the methylated CpGs, and white dots indicate the unmethylated CpGs
in each sequenced clone. The numbers shown are relative to the BMRF1 tran-
script start site.
FIG 8 BZLF1-expressing cells have decreased expression of CD74 and MHC I.
Dual-color immunohistochemistry was performed using anti-EBNA2 or anti-
BZLF1 (black) and anti-CD74 or anti-MHC I (pink) antibodies on DLBCLs
from OKT3-treated animals. EBNA2 costaining was performed on a WT
EBV-infected DLBCL, while BZLF1 costaining was performed on an SL mu-
tant EBV-infected DLBCL. Examples of EBNA2 and CD74 or MHCI coexpres-
sion are indicated by black arrows; examples of BZLF1-positive cells lacking
CD74 or MHCI are indicated by blue arrows.
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had so few EBER cells that Z coexpression could not be reliably
evaluated. These results suggest that hNSG(thy) mice infected
with the SL mutant initially express Z in a subset of virally infected
B cells, but that by day 60, the lymphoma-free mice have success-
fully established viral latency.
DISCUSSION
Although the latent and lytic forms of EBV infection are both
essential for long-term success of the virus, it has been difficult to
study the various effects of primary lytic viral infection in vitro due
to the lack of permissive cell lines that support lytic infection. Here
we have used a new humanized model, in which both human
CD34 hematopoietic stem cells and human thymic tissue are
engrafted into NSG mice, to explore the effect of enhanced lytic
EBV gene expression on EBV pathogenesis and lymphoma forma-
tion in the presence and absence of an antibody (OKT3) that in-
hibits T-cell function. These studies were made feasible by the
construction of a new superlytic (SL) EBV mutant missing three
negatively regulating elements (two ZEB motifs and the ZIIR ele-
ment) in the BZLF1 IE promoter. Our results show that although
B cells infected with the SL mutant are much more likely to express
Z than B cells infected with the WT virus, the two viruses are
surprisingly similar in their ability to induce lymphomas (in the
presence and absence of OKT3 treatment) and to establish persis-
tent tumor-free viral latency. Furthermore, our results show that
Z-expressing lymphoma cells in this mouse model contain an
abortively lytic form of viral infection that does not appear to
inhibit lymphoma cell growth and is associated with decreased
expression of MHC class I and CD74. Finally, we find that OKT3
treatment dramatically impairs the ability of hNSG(thy) mice to
control either the WT or SL viruses and allows the development of
lymphomas with a greatly increased number of LMP1-expressing
cells.
The finding that the SL mutant can establish long-term viral
latency in some hNSG(thy) mice was not completely unexpected
since activation of Z transcription requires not only the inhibition
of negatively regulating factors, but also the presence of positively
regulating factors. In contrast to studies performed in vitro, in the
hNSG(thy) model, EBV-infected B cells are often surrounded by T
cells and are exposed to a variety of different signals from neigh-
boring cells that may influence the activity of the Z promoter. For
example, since CD40 signaling has been reported to inhibit lytic
reactivation of EBV-infected B cells in vitro (2), the CD40 ligand
expressed on the surface of activated CD4 T cells may inhibit Z
expression in EBV-infected B cells in hNSG(thy) mice. Further-
more, both LMP1 and LMP2A have been reported to inhibit lytic
viral reactivation in vitro, and we found that LMP1/LMP2A ex-
pression and early lytic viral protein expression are mutually ex-
clusive in SL virus-infected lymphoma cells. Although the exact
mechanism or mechanisms by which CD40 signaling and the
LMP1 and LMP2A proteins inhibit lytic reactivation are not to-
tally defined, our results here suggest that the mutated SL virus is
still responsive to inhibition by these factors. Another interesting
possibility to explain the lack of cells coexpressing Z and LMP1
would be that Z inhibits expression of LMP1.
A perhaps more surprising result is our finding that high-level
Z expression in a relatively large percentage of EBV-infected lym-
phoma cells (up to 30% of tumor cells in the OKT3-treated ani-
mals) did not appreciably inhibit lymphoma formation or tumor
cell division in the hNSG(thy) model. The continued viability of
Z-expressing lymphoma cells can be at least partially attributed to
the unexpectedly low expression of the late lytic viral proteins in
FIG 9 OKT3 treatment greatly increases LMP1 and LMP2A expression in lymphoma cells. Dual-color immunohistochemistry was performed using anti-EBNA2
(black) and anti-LMP1 (pink) antibodies in DLBCLs from WT EBV-infected animals (A and C) and a DLBCL from a WT EBV-infected animal that had been
treated with OKT3 antibody (B). Examples of EBNA2-positive cells costaining with LMP1 are indicated by black arrows in panel B. An example of a cell with type
IIA latency (LMP1 EBNA2) is indicated by a red arrow in panel C. All pictures are at 100 magnification.
FIG 10 BZLF1/BMRF1 and LMP1/LMP2A expression are mutually exclusive. Dual-color immunohistochemistry was performed using anti-BZLF1 or anti-
BMRF1 (black) and anti-LMP1 or anti-LMP2A (pink) antibodies as indicated on SL EBV-infected DLBCLs from OKT3-treated animals. Cells expressing only
BZLF1or BMRF1 are indicated by black arrows, while cells expressing only LMP1 or LMP2A are indicated by red arrows.
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Z-expressing cells in this model. Consistent with the lack of late
viral protein expression in the Z-expressing lymphoma cells, the
circulating viral loads of animals infected with the WT and SL
viruses were similar, and the high viral loads that occurred in some
OKT3-treated animals were eliminated by prior DNase I treat-
ment (indicating that the viral DNA was derived from lysed lym-
phoma cells rather than packaged viral particles). Thus, most Z-
expressing B cells in the hNSG(thy) animal model appear to have
an “abortive” form of lytic gene expression that does not result in
release of infectious viral particles or killing of host cells.
The high number of Z-positive SL virus-infected lymphoma
cells in the hNSG(thy) model (particularly in animals treated with
the anti-CD3 antibody) has allowed us to make some new obser-
vations with regard to the effects of high-level Z expression in
EBV-infected lymphoma cells. For example, in contrast to the
predictions of previous in vitro studies, we found that Z expression
per se (in the absence of fully lytic viral infection) does not inhibit
proliferation of EBV-infected lymphoma cells. We were also able
to confirm that some potentially important previous in vitro ob-
servations are valid in the hNSG(thy) model. For example, we
confirmed that Z-expressing cells often lack CD74 expression,
which may provide one explanation for the relative inability of
CD4 T cells to eliminate Z-expressing cells in this model. CD74 is
essential for presentation of antigens via the MHC class II pathway
to CD4 cells (45) and may also play a role in MHC class I presen-
tation to CD8 T cells in dendritic cells (4). Although CD74 expres-
sion has been reported to be required for the continued viability of
B cells (24), a recent report suggested that expression of the EBV-
encoded early lytic BHRF1 protein (a BCL2 homologue) allows
Z-expressing cells to survive in the absence of CD74 expression
(71). Although we could not confirm whether the SL virus-in-
fected lymphoma cells express the BHRF1 protein (since commer-
cially available anti-BHRF1 antibodies are not suitable for immu-
nohistochemical studies in paraffin-fixed tissues), we speculate
that enhanced BHRF1 expression may promote the viability of
Z-expressing lymphoma cells. Since a recent study revealed that
the EBV EBNA-3B latency protein inhibits DLBCL formation in
humanized NSG mice by promoting T-cell infiltration (65), we
also attempted to examine EBNA-3B expression in the WT versus
SL virus-infected animals, but were unable to do so due to the
current lack of a suitable EBNA-3B antibody for IHC.
The finding that most Z-expressing B cells do not express early
or late lytic viral proteins in the hNSG(thy) model is consistent
with our recent finding that the B-cell-specific transcription fac-
tor, Oct-2, inhibits Z transcriptional function (54). The EBV-in-
fected lymphoma cells in this animal model were confirmed to
express Oct-2 (data not shown). T-cell-mediated effects may also
contribute to the low level of early lytic viral protein expression (in
comparison to Z expression) in this model, since early lytic viral
protein expression was substantially increased in SL virus-infected
animals treated with OKT3. Although this result may be due to
enhanced T-cell recognition and killing of cells expressing multi-
ple different early lytic viral antigens, it may also reflect the loss of
T-cell-derived signaling (such as CD40L) that promotes viral la-
tency in Z-expressing B cells (2). Since late viral protein expression
was not observed even in the presence of the OKT3 antibody treat-
ment, and viral loads were similar in the WT- and SL virus-in-
fected animals, we conclude that most Z-expressing lymphoma
cells do not support lytic EBV replication due to intrinsic resis-
tance. Phosphorylation of Z residue S173 is required for viral rep-
lication in vitro (but not for early lytic gene expression) (17). Thus,
an interesting possibility is that Z does not become phosphory-
lated at residue 173 in the lymphoma cells. However, our studies
do not completely exclude the possibility that cells with fully lytic
infection are so rapidly killed (by the virus or the host response)
that they are difficult to detect.
In any event, our results here clearly show that EBV has en-
coded multiple different redundant mechanisms for ensuring the
efficient establishment of viral latency in B cells, and restricting the
fully lytic form of viral infection to appropriate cell types such as
plasma cells and oropharyngeal epithelial cells. Consistent with
our results here in the hNSG(thy) model, a recent modeling study
suggested that almost all of the infectious EBV particles in human
saliva are derived from virus replicated within the oropharyngeal
epithelial cells, rather than B cells (26). Nevertheless, since lytically
infected B cells traveling through the oropharyngeal tissue are
thought to be required for infection of the oropharyngeal epithe-
lial cells (7), the ability of EBV to produce infectious viral particles
from rare B cells is presumably essential for viral transmission
from host to host. Since plasma cell differentiation appears to be
relatively infrequent in the hNSG(thy) model (data not shown),
and human oropharyngeal epithelial cells are not engrafted in this
model, the fully lytic form of EBV infection may be underrepre-
sented. Of note, since one of the three SL virus-infected, OKT3-
treated, animals had a high viral load (500 copies of EBV per ml of
plasma) at day 12 postinfection, lytic viral replication may occur
to at least some extent at early time points in the hNSG(thy)
model.
Although the results here suggest that “lytic” induction therapy
for EBV-positive tumors may be more difficult to achieve than
FIG 11 The SL mutant establishes tumor-free viral latency in some
hNSG(thy) mice by day 60 postinfection. EBER1, EBNA1, and BZLF1 staining
was performed on spleens of WT and SL mutant EBV-infected animals (not
treated with OKT3) sacrificed at different days (D) postinfection as indicated
(40 magnification). Examples of BZLF1-staining cells are indicated by ar-
rows at the earlier time points, but at day 60, none of these tumor-free animals
still had BZLF1-expressing cells.
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previously envisioned, they certainly do not preclude the further
development of this therapy. Lytic induction therapy involves a
two-tiered approach that includes not only the use of agents to
activate BZLF1 expression (for example, histone deacetylase
[HDAC] inhibitors), but also the delivery of prodrugs (e.g., gan-
ciclovir) that can be specifically converted to cytotoxic agents by
the EBV-encoded protein kinase (14, 20, 21, 64) or thymidine
kinase (radioactively labeled 2=-fluoro-2=-deoxy-beta-D-5-iodou-
racil-arabinofuranoside [FIAU]) (23). Since the EBV-encoded ki-
nases are both encoded by early lytic genes, and most of the tumor
cell killing in this approach is mediated by the activated prodrugs,
late viral gene expression does not need to be activated in tumor
cells for lytic induction therapies to be effective. Furthermore,
since we recently showed that HDAC inhibitors dramatically de-
crease B-cell expression of Oct-2 in vitro (54), HDAC inhibitors
may be useful not only for activating Z transcription, but also for
enhancing the ability of the Z protein to activate expression of the
two early lytic viral kinase genes.
In this report, we also demonstrate that functional T cells are
absolutely essential for the control of EBV infection in the
hNSG(thy) model, since all EBV-infected animals (regardless of
whether they were infected with WT or SL virus) rapidly suc-
cumbed to EBV-induced lymphomas in the presence of the OKT3
antibody. In addition, we show that the number of EBNA2-
LMP1-coexpressing lymphoma cells (i.e., cells with classically de-
fined type III latency) is closely correlated with T-cell function,
since EBNA2-LMP1-coexpressing lymphoma cells are rarely ob-
served in the EBV-infected hNSG(thy) model unless the animals
are treated with OKT3. In vitro studies have shown that LMP1
protein levels in lymphoblastoid cell lines (LCLs) can differ by up
to 100-fold from cell to cell and that the LMP1 protein level within
each cell varies greatly over time (9, 38). Although LMP1 itself is
not efficiently recognized by CD8 T cells, cells that have high-
level LMP1 expression have enhanced MHC class I antigen pre-
sentation in comparison to cells that express less LMP1 and are
much more efficiently killed by cytotoxic T cells in vitro (9). In
addition, LMP1 induces CD95 expression on LCLs in vitro and
renders them susceptible to CD95L-mediated killing by T cells
(37). Furthermore, in a recent transgenic mouse model, the ability
of LMP1 to cause B-cell lymphomas required inhibition of T-cell
function (70).
Thus, LMP1-positive lymphoma cells may be preferentially
eliminated by T cells and therefore difficult to detect in EBV-
infected hNSG(thy) mice unless they are treated with the OKT3
antibody to inhibit T-cell function. The presence of a high number
of LMP1-expressing lymphoma cells in some other humanized
mouse models currently being used to study EBV pathogenesis
and lymphoma formation (which do not include transplanted hu-
man thymic tissue) (12, 59, 61, 66) suggests that the human T cells
in these models are not functioning as well as they are in our
hNSG(thy) model. Nevertheless, while our finding here that
OKT3 treatment greatly increases the number of EBNA2/LMP1-
positive cells is consistent with a model whereby LMP1-positive
cells are preferentially killed by T cells, it is also possible that T-
cell-derived signals or cytokines decrease the level of LMP1 pro-
tein in EBNA2-expressing B cells.
In humans, EBNA2 LMP1 B cells (known as “type IIB” la-
tency) have been described in mononucleosis patients, as well in
AIDS-associated lymphomas and PTLDs (27, 50). Since such cells
represent only a portion of the cells in such tumors (which also
contain EBNA2 LMP1 cells with type III latency), it has been
generally assumed that only the cells with type III latency are driv-
ing the growth of such tumors. Interestingly, a Burkitt lymphoma
was recently described in which a small portion of the primary
tumor cells (5 to 10%) expressed EBNA2 but not LMP1 (33).
Furthermore, a cell line derived from this tumor which retained
the EBNA2 LMP1 phenotype was less susceptible to various
apoptotic stimuli than a cell line derived from the same tumor that
had type I (EBNA1 only) infection. Thus, EBNA2 expression (in
the absence of LMP1) may protect tumor cells from various forms
of apoptosis and may be selected for until additional cellular mu-
tations have occurred that allow for lymphoma growth in the ab-
sence of EBNA2. Our results here also raise questions with regard
to the precise definition of type III latency in human lymphoma
specimens. In particular, what percentage of EBNA2 cells must
coexpress LMP1 for a tumor to be labeled as having type III la-
tency? Finally, our findings here suggest that high-level LMP1 ex-
pression may target EBV-infected lymphoma cells for killing in
the presence of functional T cells and that EBV-infected B cells
expressing very little (if any) LMP1 can persist as B-cell lympho-
mas. Thus, high-level LMP1 expression may inhibit lymphoma
formation in the context of an intact host cell immune system but
promote lymphoma maintenance when T-cell function is com-
promised.
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